アルツハイマー治療薬の市場規模、シェア、動向分析：製品別、エンドユーザー別、地域別、セグメント予測、2023年～2030年

アルツハイマー治療薬市場の成長と動向

GrandView Research, Inc.の最新レポートによると、アルツハイマー治療薬の世界市場規模は2030年までに151億9,000万米ドルに達する見込みです。

2023年から2030年までのCAGRは19.99%で市場は拡大すると予測されています。政府機関はアルツハイマーの支援、ケア、研究活動に資金を提供しており、これが市場成長を促進すると予測されています。例えば、2022年3月にAlzheimer's Societyは、患者のケアを改善するために認知症研究に今後数年間で約35億米ドルを費やすと発表しました。

さらに、Alzheimer's AssociationとAlzheimer's Impact Movement（AIM）は、患者のための効果的な公衆衛生下部構造を作成するために、BOLD Infrastructure for Alzheimer's Actを実施するために2,500万米ドルを利用することを発表しました。また、2021年9月、サウステキサス・アルツハイマー病センターとデューク・ノースカロライナ大学アルツハイマー病研究センターは、ADに関連する危険因子の調査を奨励するため、国立老化研究所から5年間で1,480万米ドルを授与されました。

さらに、ADに関連する認知症の発生率と費用負担の増加が、市場の成長を後押しすると予想されています。アルツハイマー協会によると、英国では約90万人が認知症を患っており、2040年には160万人に増加し、同年の認知症罹患率は20万9,600人になると予測されています。

現在の標準治療は症状を緩和する薬に限られています。そのため、疾患修飾性の抗アミロイド治療薬が承認されれば、治療の展望が変わると期待されています。例えば、2021年6月、米国FDAはアルツハイマー病患者の治療薬としてアドヘルム（アデュカヌマブ）の早期承認を認めました。これはモノクローナル抗体で、患者の脳内に存在するアミロイドβのクラスター型を標的とし、その形成を阻止します。後期臨床試験段階にある他の主要な抗アミロイドモノクローナル抗体には、Gantenerumab（F. Hoffmann-La Roche Ltd.）、Solanezumab（Eli Lilly and Company）、Lecanemab（Eisai Inc./Biogen）などがあります。

アルツハイマー治療薬市場レポートハイライト

• 製品別では、コリンエステラーゼ阻害薬が現在の標準治療薬であるため、2022年にはコリンエステラーゼ阻害薬セグメントが最大の売上シェアを占める。2022年3月、米国FDAはCorium Inc.が開発したコリンエステラーゼ阻害薬Adlarity（塩酸ドネペジル）をAD患者の治療薬として承認した
• パイプライン医薬品は、強力な製品パイプラインの存在と予測期間中の上市が見込まれることから、予測期間中に最も速い成長が見込まれます。AD治療のための抗アミロイドβ原線維抗体であるバイオジェン社の製品lecanemab（BAN2401）は、現在第3相臨床試験中です。
• 入院率の高さから、病院薬局のエンドユーザー分野が2022年の市場を独占しました。アルツハイマー病協会（Alzheimer's Association）の報告書（2022年）別と、メディケア受給者の約32％がアルツハイマー病患者であり、毎年少なくとも1回は退院しています。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • セグメントの定義
• 地域の範囲
• 推定・予測のタイムライン
• 目的
• 調査手法
• 情報調達
  • 購入したデータベース
  • Gvrの内部データベース
  • 二次情報
  • 1次調査
• 情報またはデータ分析
  • データ分析モデル
• 市場の形成と検証
• モデル詳細
  • 商品フロー分析
• 二次情報のリスト
• 略語のリスト

第2章 エグゼクティブサマリー

• 市場スナップショット
• セグメントのスナップショット
• 競合情勢のスナップショット

第3章 市場変数、動向、および範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/補助的な市場見通し
• 市場動向と展望
• 市場力学
  • アルツハイマー病の有病率の増加
  • アルツハイマー病に対する強力なパイプライン薬の存在
  • 革新的な技術のイントロダクション
  • 政府の資金援助と取り組みの増加
  • 啓発プログラムの増加
• 市場抑制要因分析
  • 厳格な規制枠組みの存在
  • 臨床試験の失敗率が高い
• 事業環境分析
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析

第4章 製品のビジネス分析

• アルツハイマー治療薬市場：変動分析
  • コリンエステラーゼ阻害剤
  • N-メチル-D-アスパラギン酸（Nmda）受容体拮抗薬
  • 配合剤
  • パイプライン医薬品

第5章 エンドユーザーのビジネス分析

• アルツハイマー治療薬市場：変動分析
  • 病院薬局
  • 小売薬局
  • eコマース

第6章 地域のビジネス分析

• 地域別アルツハイマー治療薬市場シェア、2022年および2030年
• 北米
  • SWOT分析
  • 北米アルツハイマー治療薬市場、2018～2030年
  • 米国
  • カナダ
• 欧州
  • SWOT分析
  • 欧州のアルツハイマー治療薬市場、2018～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • SWOT分析
  • アジア太平洋地域のアルツハイマー治療薬市場、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • SWOT分析
  • ラテンアメリカのアルツハイマー治療薬市場、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• MEA
  • SWOT分析
  • MEAアルツハイマー治療薬市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業の分類
• 戦略マッピング
• 主要企業の市場シェア分析、2022年
• 企業プロファイル
  • EISAI CO., LTD.
  • NOVARTIS AG
  • ABBVIE INC.（ALLERGAN PLC.）
  • ADAMAS PHARMACEUTICALS, INC.
  • H. LUNDBECK A/S
  • BIOGEN
  • AC IMMUNE
  • F. HOFFMANN LA ROCHE LTD.
  • DAIICHI SANKYO COMPANY, LIMITED
  • JOHNSON &JOHNSON SERVICES, INC.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Alzheimer's Therapeutics Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 5 Global Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 6 Global Alzheimer's Therapeutics Market, by Region, 2018 - 2030 (USD Million)
• Table 7 North America Alzheimer's Therapeutics Market, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 9 North America Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 10 U.S. Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 11 U.S. Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 12 Canada Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 13 Canada Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 14 Europe Alzheimer's Therapeutics Market, by Country, 2018 - 2030 (USD Million)
• Table 15 Europe Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 16 Europe Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 17 Germany Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 18 Germany Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 19 UK Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 20 UK Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 21 France Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 22 France Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 23 Italy Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 24 Italy Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 25 Spain Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 26 Spain Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 27 Denmark Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 28 Denmark Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 29 Sweden Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 30 Sweden Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 31 Norway Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 32 Norway Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific Alzheimer's Therapeutics Market, by Country, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 36 China Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 37 China Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 38 Japan Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 39 Japan Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 40 India Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 41 India Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 42 South Korea Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 43 South Korea Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 44 Australia Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 45 Australia Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 46 Thailand Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 47 Thailand Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 48 Latin America Alzheimer's Therapeutics Market, by Country, 2018 - 2030 (USD Million)
• Table 49 Latin America Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 50 Latin America Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 51 Brazil Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 52 Brazil Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 53 Mexico Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 54 Mexico Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 55 Argentina Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 56 Argentina Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Alzheimer's Therapeutics Market, by Country, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 59 Middle East & Africa Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 60 South Africa Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 61 South Africa Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 63 Saudi Arabia Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 64 UAE Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 65 UAE Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)
• Table 66 Kuwait Alzheimer's Therapeutics Market, by Product, 2018 - 2030 (USD Million)
• Table 67 Kuwait Alzheimer's Therapeutics Market, by End-user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Alzheimer's Therapeutics Market Segmentation
• Fig. 8 Market Snapshot, 2022
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Global Alzheimer's Therapeutics Market: by Product Movement Analysis
• Fig. 15 Global Alzheimer's Therapeutics Market, for Cholinesterase inhibitors, 2018 - 2030 (USD Million)
• Fig. 16 Global Alzheimer's Therapeutics Market, for Donepezil, 2018 - 2030 (USD Million)
• Fig. 17 Global Alzheimer's Therapeutics Market, for Galantamine, 2018 - 2030 (USD Million)
• Fig. 18 Global Alzheimer's Therapeutics Market, for Rivastigmine, 2018 - 2030 (USD Million)
• Fig. 19 Global Alzheimer's Therapeutics Market, for N-methyl-D-aspartate receptor antagonist, 2018 - 2030 (USD Million)
• Fig. 20 Global Alzheimer's Therapeutics Market, for Combination drug, 2018 - 2030 (USD Million)
• Fig. 21 Global Alzheimer's Therapeutics Market, for Pipeline drugs, 2018 - 2030 (USD Million)
• Fig. 22 Global Alzheimer's Therapeutics Market: End user Movement Analysis
• Fig. 23 Global Alzheimer's Therapeutics Market, for Pharmaceutical & Biotechnology Companies, 2018 - 2030 (USD Million)
• Fig. 24 Global Alzheimer's Therapeutics Market, for Hospital pharmacy, 2018 - 2030 (USD Million)
• Fig. 25 Global Alzheimer's Therapeutics Market, for Retail pharmacy, 2018 - 2030 (USD Million)
• Fig. 26 Global Alzheimer's Therapeutics Market, for E-commerce, 2018 - 2030 (USD Million)
• Fig. 27 Regional Marketplace: Key Takeaways Alzheimer's Therapeutics Market, Region 2018 - 2030 (USD Million)
• Fig. 28 Alzheimer's Therapeutics Market :Regional Outlook, 2022 & 2030 2018 - 2030 (USD Million)
• Fig. 29 North America Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 30 U.S. Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 31 Canada Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 32 Europe Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 33 Germany Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 34 UK Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 35 France Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 36 Italy Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 37 Spain Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 38 Denmark Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 39 Sweden Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 40 Norway Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 41 Asia Pacific Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 42 Japan Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 43 China Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 44 India Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 45 Australia Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 46 South Korea Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 47 Thailand Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 48 Latin America Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 49 Brazil Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 50 Mexico Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 51 Argentina Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 52 Middle East and Africa Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 53 South Africa Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 54 Saudi Arabia Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 55 UAE Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• Fig. 56 Kuwait Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)

Alzheimer's Therapeutics Market Growth & Trends

The global Alzheimer's therapeutics market size is expected to reach USD 15.19 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 19.99% from 2023 to 2030. Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth. For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.

Additionally, the Alzheimer's Association with the Alzheimer's Impact Movement (AIM) announced to utilize USD 25 million to implement the BOLD Infrastructure for Alzheimer's Act to create an effective public health substructure for patients. In addition, in September 2021, the South Texas Alzheimer's Disease Center and the Duke/University of North Carolina Alzheimer's Disease Research Center were granted USD 14.8 million over five years by the National Institute of Aging to encourage research on risk factors related to AD.

Furthermore, an increase in the incidence and cost burden of dementia associated with AD is expected to boost the market growth. According to the Alzheimer's Society, around 900,000 people are living with dementia in the United Kingdom, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.

The current standard of care is limited to symptom-relieving drugs. Therefore, the approval of disease-modifying anti-amyloid therapeutics is expected to change the treatment landscape. For instance, in June 2021, the U.S. FDA granted accelerated approval to Aduhelm (aducanumab) for the treatment of patients with Alzheimer's disease. It is a monoclonal antibody that targets cluster forms of amyloid beta present in the brains of patients and stops its formation. Other key anti-amyloid monoclonal antibodies in late-stage clinical trials include Gantenerumab (F. Hoffmann-La Roche Ltd.), Solanezumab (Eli Lilly and Company), and Lecanemab (Eisai Inc./Biogen), among others.

Alzheimer's Therapeutics Market Report Highlights

• By product, the cholinesterase inhibitors segment held the largest revenue share in 2022 as it is the current standard of care. In March 2022, the U.S. FDA approved the cholinesterase inhibitor Adlarity (donepezil hydrochloride) developed by Corium Inc. for the treatment of patients with AD
• Pipeline drugs are anticipated to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and their expected launch during the forecast period. Biogen's product lecanemab (BAN2401), an anti-amyloid beta protofibril antibody for treating AD, is currently in phase 3 clinical trials
• The hospital pharmacy end-user segment dominated the market in 2022 owing to the high hospitalization rate. According to Alzheimer's Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer's have at least one hospital discharge annually

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Product Segment
    • 1.1.1.2 End-User Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends And Outlook
• 3.4. Market Dynamics
  • 3.4.1. Increasing Prevalence Of Alzheimer's Disease
  • 3.4.2. Presence Of Strong Pipeline Drugs For Alzheimer's Disease
  • 3.4.3. Introduction Of Innovative Technologies
  • 3.4.4. Increase In Government Funding And Initiatives
  • 3.4.5. Increase In Awareness Programs
• 3.5. Market Restraint Analysis
  • 3.5.1. Presence Of Stringent Regulatory Framework
  • 3.5.2. High Clinical Trial Failures
• 3.6. Business Environment Analysis
  • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

• 4.1 Alzheimer's Therapeutics Market: Drug Class Movement Analysis
  • 4.1.1 Cholinesterase Inhibitors
    • 4.1.1.1 Cholinesterase Inhibitors Market Estimates And Forecast, 2018 - 2030
    • 4.1.1.1.1 Donepezil Inhibitors Market Estimates And Forecast, 2018 - 2030
    • 4.1.1.1.2 Galantamine Inhibitors Market Estimates And Forecast, 2018 - 2030
    • 4.1.1.1.3 Rivastigmine Inhibitors Market Estimates And Forecast, 2018 - 2030
  • 4.1.2 N-Methyl-D-Aspartate (Nmda) Receptor Antagonist
    • 4.1.2.1 N-Methyl-D-Aspartate (Nmda) Receptor Antagonist Market Estimates And Forecast, 2018 - 2030
  • 4.1.3 Combination Drug
    • 4.1.3.1 Combination Drug Market Estimates And Forecast, 2018 - 2030
  • 4.1.4 Pipeline Drugs
    • 4.1.4.1 Pipeline Drugs Market Estimates And Forecast, 2018 - 2030

Chapter 5. End User Business Analysis

• 5.1 Alzheimer's Therapeutics Market: End User Movement Analysis
  • 5.1.1 Hospital Pharmacy
    • 5.1.1.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030
  • 5.1.2 Retail Pharmacy
    • 5.1.2.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030
  • 5.1.3 E-Commerce
    • 5.1.3.1 E-Commerce Market Estimates And Forecast, 2018 - 2030

Chapter 6. Regional Business Analysis

• 6.1. Alzheimer's Therapeutics Market Share By Region, 2022 & 2030
• 6.2. North America
  • 6.2.1. Swot Analysis
  • 6.2.2. North America Alzheimer's Therapeutics Market, 2018 - 2030 (Usd Million)
  • 6.2.3. U.S.
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Competitive Scenario
    • 6.2.3.4. Regulatory Framework
    • 6.2.3.5. Reimbursement Scenario
    • 6.2.3.6. U.S. Alzheimer's Therapeutics Market, 2018 - 2030 (Usd Million)
  • 6.2.4. Canada
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Competitive Scenario
    • 6.2.4.4. Regulatory Framework
    • 6.2.4.5. Reimbursement Scenario
    • 6.2.4.6. Canada Alzheimer's Therapeutics Market, 2018 - 2030 (Usd Million)
• 6.3. Europe
  • 6.3.1. Swot Analysis
  • 6.3.2. Europe Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.3. Germany
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Competitive Scenario
    • 6.3.3.4. Regulatory Framework
    • 6.3.3.5. Reimbursement Scenario
    • 6.3.3.6. Germany Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.4. UK
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Competitive Scenario
    • 6.3.4.4. Regulatory Framework
    • 6.3.4.5. Reimbursement Scenario
    • 6.3.4.6. UK Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.5. France
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Competitive Scenario
    • 6.3.5.4. Regulatory Framework
    • 6.3.5.5. Reimbursement Scenario
    • 6.3.5.6. France Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.6. Italy
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Competitive Scenario
    • 6.3.6.4. Regulatory Framework
    • 6.3.6.5. Reimbursement Scenario
    • 6.3.6.6. Italy Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.7. Spain
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Competitive Scenario
    • 6.3.7.4. Regulatory Framework
    • 6.3.7.5. Reimbursement Scenario
    • 6.3.7.6. Spain Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.8. Denmark
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Competitive Scenario
    • 6.3.8.4. Regulatory Framework
    • 6.3.8.5. Reimbursement Scenario
    • 6.3.8.6. Denmark Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.9. Sweden
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Competitive Scenario
    • 6.3.9.4. Regulatory Framework
    • 6.3.9.5. Reimbursement Scenario
    • 6.3.9.6. Sweden Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.3.10. Norway
    • 6.3.10.1. Key Country Dynamics
    • 6.3.10.2. Target Disease Prevalence
    • 6.3.10.3. Competitive Scenario
    • 6.3.10.4. Regulatory Framework
    • 6.3.10.5. Reimbursement Scenario
    • 6.3.10.6. Norway Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. SWOT Analysis
  • 6.4.2. Asia Pacific Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.3. Japan
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Regulatory Framework
    • 6.4.3.5. Reimbursement Scenario
    • 6.4.3.6. Japan Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.4. China
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Competitive Scenario
    • 6.4.4.4. Regulatory Framework
    • 6.4.4.5. Reimbursement Scenario
    • 6.4.4.6. China Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.5. India
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Competitive Scenario
    • 6.4.5.4. Regulatory Framework
    • 6.4.5.5. Reimbursement Scenario
    • 6.4.5.6. India Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.6. South Korea
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Competitive Scenario
    • 6.4.6.4. Regulatory Framework
    • 6.4.6.5. Reimbursement Scenario
    • 6.4.6.6. South Korea Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.7. Australia
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Competitive Scenario
    • 6.4.7.4. Regulatory Framework
    • 6.4.7.5. Reimbursement Scenario
    • 6.4.7.6. Australia Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.4.8. Thailand
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Competitive Scenario
    • 6.4.8.4. Regulatory Framework
    • 6.4.8.5. Reimbursement Scenario
    • 6.4.8.6. Thailand Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. SWOT Analysis
  • 6.5.2. Latin America Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.5.3. Brazil
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Regulatory Framework
    • 6.5.3.5. Reimbursement Scenario
    • 6.5.3.6. Brazil Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Regulatory Framework
    • 6.5.4.5. Reimbursement Scenario
    • 6.5.4.6. Mexico Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.5.5. Argentina
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Regulatory Framework
    • 6.5.5.5. Reimbursement Scenario
    • 6.5.5.6. Argentina Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. SWOT Analysis
  • 6.6.2. MEA Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.6.3. South Africa
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. Regulatory Framework
    • 6.6.3.5. Reimbursement Scenario
    • 6.6.3.6. South Africa Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.6.4. Saudi Arabia
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. Regulatory Framework
    • 6.6.4.5. Reimbursement Scenario
    • 6.6.4.6. Saudi Arabia Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.6.5. UAE
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Regulatory Framework
    • 6.6.5.5. Reimbursement Scenario
    • 6.6.5.6. UAE Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)
  • 6.6.6. Kuwait
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Regulatory Framework
    • 6.6.6.5. Reimbursement Scenario
    • 6.6.6.6. Kuwait Alzheimer's Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Key Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.4.1 EISAI CO., LTD.
    • 7.4.1.1 Company overview
    • 7.4.1.2 Financial performance
    • 7.4.1.3 Product benchmarking
    • 7.4.1.4 Strategic Initiatives
  • 7.4.2 NOVARTIS AG
    • 7.4.2.1 Company overview
    • 7.4.2.2 Financial performance
    • 7.4.2.3 Product benchmarking
    • 7.4.2.4 Strategic Initiatives
  • 7.4.3 ABBVIE INC. (ALLERGAN PLC.)
    • 7.4.3.1 Company overview
    • 7.4.3.2 Financial performance
    • 7.4.3.3 Product benchmarking
    • 7.4.3.4 Strategic Initiatives
  • 7.4.4 ADAMAS PHARMACEUTICALS, INC.
    • 7.4.4.1 Company overview
    • 7.4.4.2 Product benchmarking
    • 7.4.4.3 Strategic Initiatives
  • 7.4.5 H. LUNDBECK A/S
    • 7.4.5.1 Company overview
    • 7.4.5.2 Financial performance
    • 7.4.5.3 Product benchmarking
    • 7.4.5.4 Strategic Initiatives
  • 7.4.6 BIOGEN
    • 7.4.6.1 Company overview
    • 7.4.6.2 Financial performance
    • 7.4.6.3 Product benchmarking
    • 7.4.6.4 Strategic Initiatives
  • 7.4.7 AC IMMUNE
    • 7.4.7.1 Company overview
    • 7.4.7.2 Financial performance
    • 7.4.7.3 Product benchmarking
    • 7.4.7.4 Strategic Initiatives
  • 7.4.8 F. HOFFMANN LA ROCHE LTD.
    • 7.4.8.1 Company overview
    • 7.4.8.2 Financial performance
    • 7.4.8.3 Product benchmarking
    • 7.4.8.4 Strategic Initiatives
  • 7.4.9 DAIICHI SANKYO COMPANY, LIMITED
    • 7.4.9.1 Company overview
    • 7.4.9.2 Financial performance
    • 7.4.9.3 Product benchmarking
    • 7.4.9.4 Strategic Initiatives
  • 7.4.10 JOHNSON & JOHNSON SERVICES, INC.
    • 7.4.7.1 Company overview
    • 7.4.7.2 Financial performance
    • 7.4.7.3 Product benchmarking
    • 7.4.7.4 Strategic Initiatives